AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 308.4 USD | -0.55% |
|
+3.00% | +7.09% |
| 05-13 | Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating | MT |
| 05-09 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.42% | 29 M€ | -.--% | - | |
| 0.42% | 322 M€ | +13.88% | ||
| 0.42% | 8 M€ | +5.74% | - | |
| 0.42% | 744 M€ | +8.90% | ||
| 0.41% | 50 M€ | +9.46% | ||
| 0.39% | 205 M€ | -.--% | ||
| 0.35% | 34 M€ | +11.93% | - | |
| 0.35% | 57 M€ | +20.30% | - | |
| 0.34% | 9 M€ | +9.07% | - | |
| 0.33% | 2,517 M€ | +12.09% | - | |
| 0.33% | 36 M€ | +22.19% | ||
| 0.29% | 283 M€ | +19.31% | ||
| 0.29% | 36 M€ | +2.47% | - | |
| 0.26% | 4 M€ | -.--% | - | |
| 0.25% | 1 M€ | +3.03% | - | |
| 0.25% | 14 M€ | +16.19% | - | |
| 0.25% | 1,166 M€ | +0.26% | ||
| 0.25% | 607 M€ | +0.05% | ||
| 0.25% | 23 M€ | +7.25% | - | |
| 0.24% | 23 M€ | -.--% | - | |
| 0.24% | 786 M€ | -.--% |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
308.4
USD
Average target price
314.6
USD
Spread / Average Target
+2.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.09% | 166B | |
| +29.98% | 684B | |
| +30.34% | 568B | |
| -3.52% | 361B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| -1.22% | 159B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.
